



Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747 Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM Received : 29/Oct/2024 11:31AM Reported : 29/Oct/2024 01:17PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF HAEMATOLOGY

PERIPHERAL SMEAR, WHOLE BLOOD EDTA

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE. NO HEMOPARASITES SEEN.



Page 1 of 13



Dr.Kritika Jain M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:BED240242789





Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747

Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM

Received : 29/Oct/2024 11:31AM Reported : 29/Oct/2024 01:17PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF HAEMATOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HEMOGRAM , WHOLE BLOOD EDTA				
HAEMOGLOBIN	12.9	g/dL	13-17	Spectrophotometer
PCV	39.80	%	40-50	Electronic pulse & Calculation
RBC COUNT	4.57	Million/cu.mm	4.5-5.5	Electrical Impedence
MCV	87	fL	83-101	Calculated
MCH	28.3	pg	27-32	Calculated
MCHC	32.4	g/dL	31.5-34.5	Calculated
R.D.W	13	%	11.6-14	Calculated
TOTAL LEUCOCYTE COUNT (TLC)	8,200	cells/cu.mm	4000-10000	Electrical Impedance
DIFFERENTIAL LEUCOCYTIC COUNT (I	DLC)			
NEUTROPHILS	60	%	40-80	Electrical Impedance
LYMPHOCYTES	30	%	20-40	Electrical Impedance
EOSINOPHILS	04	%	1-6	Electrical Impedance
MONOCYTES	06	%	2-10	Electrical Impedance
BASOPHILS	00	%	<1-2	Electrical Impedance
ABSOLUTE LEUCOCYTE COUNT				
NEUTROPHILS	4920	Cells/cu.mm	2000-7000	Calculated
LYMPHOCYTES	2460	Cells/cu.mm	1000-3000	Calculated
EOSINOPHILS	328	Cells/cu.mm	20-500	Calculated
MONOCYTES	492	Cells/cu.mm	200-1000	Calculated
Neutrophil lymphocyte ratio (NLR)	2		0.78- 3.53	Calculated
PLATELET COUNT	244000	cells/cu.mm	150000-410000	Electrical impedence
ERYTHROCYTE SEDIMENTATION RATE (ESR)	22	mm at the end of 1 hour	0-15	Modified Westergren
ERIPHERAL SMEAR				

RBCs ARE NORMOCYTIC NORMOCHROMIC.

TLC, DLC WITHIN NORMAL LIMIT. NO IMMATURE CELLS ARE SEEN.

PLATELETS ARE ADEQUATE.

NO HEMOPARASITES SEEN.

Page 2 of 13



Dr.Kritika Jain

M.B.B.S,M.D(Pathology)

Consultant Pathologist

SIN No:BED240242789





Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747

Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM Received : 29/Oct/2024 11:31AM

Reported : 29/Oct/2024 04:39PM

: Final Report : ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF HAEMATOLOGY

Status

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method		
BLOOD GROUP ABO AND RH FACTOR, WHOLE BLOOD EDTA						
BLOOD GROUP TYPE	В			Forward & Reverse Grouping with Slide/Tube Aggluti		
Rh TYPE	POSITIVE			Forward & Reverse Grouping with Slide/Tube Agglutination		



Page 3 of 13



Dr.Kritika Jain M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:BED240242789





Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747

Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM

Received : 29/Oct/2024 11:38AM Reported : 29/Oct/2024 01:22PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GLUCOSE, FASTING, NAF PLASMA	107	mg/dL	70-100	GOD - POD

Comment:

As per American Diabetes Guidelines, 2023

Fasting Glucose Values in mg/dL	Interpretation
70-100 mg/dL	Normal
100-125 mg/dL	Prediabetes
≥126 mg/dL	Diabetes
<70 mg/dL	Hypoglycemia

Note:

- 1. The diagnosis of Diabetes requires a fasting plasma glucose of > or = 126 mg/dL and/or a random / 2 hr post glucose value of > or = 200 mg/dL on at least 2 occasions.
- 2. Very high glucose levels (>450 mg/dL in adults) may result in Diabetic Ketoacidosis & is considered critical.

Page 4 of 13

Dr.Kritika Jain M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:PLF02210738







Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747

Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM

Received : 29/Oct/2024 03:54PM Reported : 29/Oct/2024 05:01PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
HBA1C (GLYCATED HEMOGLOBIN),	WHOLE BLOOD EDTA			
HBA1C, GLYCATED HEMOGLOBIN	6	%		HPLC
ESTIMATED AVERAGE GLUCOSE (eAG)	126	mg/dL		Calculated

Comment:

Reference Range as per American Diabetes Association (ADA) 2023 Guidelines:

REFERENCE GROUP	HBA1C %
NON DIABETIC	<5.7
PREDIABETES	5.7 - 6.4
DIABETES	≥ 6.5
DIABETICS	1 4 CO . 1 4 CO
EXCELLENT CONTROL	6 – 7
FAIR TO GOOD CONTROL	7 – 8
UNSATISFACTORY CONTROL	8 – 10
POOR CONTROL	>10

Note: Dietary preparation or fasting is not required.

- 1. HbA1C is recommended by American Diabetes Association for Diagnosing Diabetes and monitoring Glycemic Control by American Diabetes Association guidelines 2023.
- 2. Trends in HbA1C values is a better indicator of Glycemic control than a single test.
- 3. Low HbA1C in Non-Diabetic patients are associated with Anemia (Iron Deficiency/Hemolytic), Liver Disorders, Chronic Kidney Disease. Clinical Correlation is advised in interpretation of low Values.
- 4. Falsely low HbA1c (below 4%) may be observed in patients with clinical conditions that shorten erythrocyte life span or decrease mean erythrocyte age. HbA1c may not accurately reflect glycemic control when clinical conditions that affect erythrocyte survival are present.
- 5. In cases of Interference of Hemoglobin variants in HbA1C, alternative methods (Fructosamine) estimation is recommended for Glycemic Control
 - A: HbF >25%
 - B: Homozygous Hemoglobinopathy.

(Hb Electrophoresis is recommended method for detection of Hemoglobinopathy)

Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:EDT240093638



Page 5 of 13





Age/Gender : 35 Y 6 M 26 D/M : RIND.0000017747 UHID/MR No

Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM Received : 29/Oct/2024 11:34AM

Reported : 29/Oct/2024 01:19PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method			
LIPID PROFILE , SERUM							
TOTAL CHOLESTEROL	180	mg/dL	<200	CHE/CHO/POD			
TRIGLYCERIDES	181	mg/dL	<150	Enzymatic			
HDL CHOLESTEROL	35	mg/dL	40-60	CHOD			
NON-HDL CHOLESTEROL	145	mg/dL	<130	Calculated			
LDL CHOLESTEROL	108.25	mg/dL	<100	Calculated			
VLDL CHOLESTEROL	36.29	mg/dL	<30	Calculated			
CHOL / HDL RATIO	5.09		0-4.97	Calculated			
ATHEROGENIC INDEX (AIP)	0.35		<0.11	Calculated			

Comment:

Reference Interval as per National Cholesterol Education Program (NCEP) Adult Treatment Panel III Report.

	Desirable	Borderline High	High	Very High
TOTAL CHOLESTEROL	< 200	200 - 239	≥ 240	
TRIGLYCERIDES	<150	150 - 199	200 - 499	≥ 500
LDL	Optimal < 100 Near Optimal 100-129	130 - 159	160 - 189	≥ 190
HDL	≥ 60			
NON-HDL CHOLESTEROL	Optimal <130; Above Optimal 130-159	160-189	190-219	>220

Page 6 of 13



Dr.Kritika Jain M.B.B.S,M.D(Pathology) Consultant Pathologist





Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747

Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM Received : 29/Oct/2024 11:34AM

Reported : 29/Oct/2024 01:19PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
IVER FUNCTION TEST (LFT) , SERUM				
BILIRUBIN, TOTAL	0.56	mg/dL	0.20-1.20	Colorimetric
BILIRUBIN CONJUGATED (DIRECT)	0.17	mg/dl	0-0.2	Diazotized sulfanilic acid
BILIRUBIN (INDIRECT)	0.39	mg/dL	0.0-1.1	Dual Wavelength
ALANINE AMINOTRANSFERASE (ALT/SGPT)	35.79	U/L	21-72	UV with P-5-P
ASPARTATE AMINOTRANSFERASE (AST/SGOT)	24.2	U/L	17-59	UV with P-5-P
AST (SGOT) / ALT (SGPT) RATIO (DE RITIS)	0.7		<1.15	Calculated
ALKALINE PHOSPHATASE	68.10	U/L	38-126	p-nitrophenyl phosphate
PROTEIN, TOTAL	7.36	g/dL	6.3-8.2	Biuret
ALBUMIN	4.42	g/dL	3.5 - 5	Bromocresol Green
GLOBULIN	2.94	g/dL	2.0-3.5	Calculated
A/G RATIO	1.5	- //	0.9-2.0	Calculated

Comment:

LFT results reflect different aspects of the health of the liver, i.e., hepatocyte integrity (AST & ALT), synthesis and secretion of bile (Bilirubin, ALP), cholestasis (ALP, GGT), protein synthesis (Albumin) Common patterns seen:

- 1. Hepatocellular Injury:
- *AST Elevated levels can be seen. However, it is not specific to liver and can be raised in cardiac and skeletal injuries.*ALT Elevated levels indicate hepatocellular damage. It is considered to be most specific lab test for hepatocellular injury. Values also correlate well with increasing BMI. Disproportionate increase in AST, ALT compared with ALP. AST: ALT (ratio) In case of hepatocellular injury AST: ALT > 1In Alcoholic Liver Disease AST: ALT usually >2. This ratio is also seen to be increased in NAFLD, Wilsons's diseases, Cirrhosis, but the increase is usually not >2.
- 2. Cholestatic Pattern:*ALP Disproportionate increase in ALP compared with AST, ALT. ALP elevation also seen in pregnancy, impacted by age and sex.*Bilirubin elevated- predominantly direct, To establish the hepatic origin correlation with elevated GGT helps.
- 3. Synthetic function impairment:*Albumin-Liver disease reduces albumin levels, Correlation with PT (Prothrombin Time) helps.
- 4. Associated tests for assessment of liver fibrosis Fibrosis-4 and APRI Index.

Page 7 of 13



Dr.Kritika Jain M.B.B.S.M.D(P

M.B.B.S,M.D(Pathology)

Consultant Pathologist





Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747

Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM

Received : 29/Oct/2024 11:34AM Reported : 29/Oct/2024 04:39PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

FT/KFT), SER	Y IN/I		
,,	UIVI		
0.94	mg/dL	0.67-1.17	Enzymatic colorimetric
19.68	mg/dL	19-43	Urease
9.2	mg/dL	8.0 - 23.0	Calculated
9.03	mg/dL	3.5-7.2	Uricase
9.90	mg/dL	8.4 - 10.2	Arsenazo-III
3.47	mg/dL	2.5-4.5	PMA Phenol
137	mmol/L	135-145	Direct ISE
4.0	mmol/L	3.5-5.1	Direct ISE
102	mmol/L	98 - 107	Direct ISE
7.36	g/dL	6.3-8.2	Biuret
4.42	g/dL	3.5 - 5	Bromocresol Green
2.94	g/dL	2.0-3.5	Calculated
1.5	V. 11	0.9-2.0	Calculated
	19.68 9.2 9.03 9.90 3.47 137 4.0 102 7.36 4.42 2.94	19.68 mg/dL 9.2 mg/dL 9.03 mg/dL 9.90 mg/dL 3.47 mg/dL 137 mmol/L 4.0 mmol/L 102 mmol/L 7.36 g/dL 4.42 g/dL 2.94 g/dL	19.68 mg/dL 19-43 9.2 mg/dL 8.0 - 23.0 9.03 mg/dL 3.5-7.2 9.90 mg/dL 8.4 - 10.2 3.47 mg/dL 2.5-4.5 137 mmol/L 135-145 4.0 mmol/L 3.5-5.1 102 mmol/L 98 - 107 7.36 g/dL 6.3-8.2 4.42 g/dL 3.5 - 5 2.94 g/dL 2.0-3.5

Page 8 of 13



Dr.Kritika Jain M.B.B.S,M.D(Pathology) Consultant Pathologist





Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747

Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM

Received : 29/Oct/2024 11:34AM Reported : 29/Oct/2024 01:19PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF BIOCHEMISTRY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
GAMMA GLUTAMYL TRANSPEPTIDASE (GGT) , SERUM	19.21	U/L	15-73	Glyclyclycine Nitoranalide



Page 9 of 13



Dr.Kritika Jain M.B.B.S,M.D(Pathology) Consultant Pathologist







Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747

Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM

Received : 29/Oct/2024 03:54PM Reported : 29/Oct/2024 05:38PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
THYROID PROFILE TOTAL (T3, T4, TSH	H), SERUM			
TRI-IODOTHYRONINE (T3, TOTAL)	1.23	ng/mL	0.87-1.78	CLIA
THYROXINE (T4, TOTAL)	10.12	μg/dL	5.48-14.28	CLIA
THYROID STIMULATING HORMONE (TSH)	3.023	μIU/mL	0.38-5.33	CLIA

Comment:

For pregnant females	Bio Ref Range for TSH in uIU/ml (As pe American Thyroid Association)		
First trimester	0.1 - 2.5		
Second trimester	0.2 - 3.0		
Third trimester	0.3 – 3.0		

- **1.** TSH is a glycoprotein hormone secreted by the anterior pituitary. TSH activates production of T3 (Triiodothyronine) and its prohormone T4 (Thyroxine). Increased blood level of T3 and T4 inhibit production of TSH.
- **2.** TSH is elevated in primary hypothyroidism and will be low in primary hyperthyroidism. Elevated or low TSH in the context of normal free thyroxine is often referred to as sub-clinical hypo- or hyperthyroidism respectively.
- **3.** Both T4 & T3 provides limited clinical information as both are highly bound to proteins in circulation and reflects mostly inactive hormone. Only a very small fraction of circulating hormone is free and biologically active.
- **4.** Significant variations in TSH can occur with circadian rhythm, hormonal status, stress, sleep deprivation, medication & circulating antibodies.

TSH	T3	T4	FT4	Conditions
High	Low	Low	Low	Primary Hypothyroidism, Post Thyroidectomy, Chronic Autoimmune Thyroiditis
High	N	N	N	Subclinical Hypothyroidism, Autoimmune Thyroiditis, Insufficient Hormone Treatment.
N/Low	Low	Low	Low	Secondary and Tertiary Hypothyroidism
Low	High	High	High	Primary Hyperthyroidism, Goitre, Thyroiditis, Drug effects, Early Pregnancy
Low	N	N	N	Subclinical Hyperthyroidism
Low	Low	Low	Low	Central Hypothyroidism, Treatment with Hyperthyroidism
Low	N	High	High	Thyroiditis, Interfering Antibodies
N/Low	High	N	N	T3 Thyrotoxicosis, Non thyroidal causes
High	High	High	High	Pituitary Adenoma; TSHoma/Thyrotropinoma

Page 10 of 13



Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24145219







Age/Gender : 35 Y 6 M 26 D/M
UHID/MR No : RIND.0000017747
Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 10:53AM

Received : 29/Oct/2024 03:54PM Reported : 29/Oct/2024 05:38PM

Status : Final Report

Sponsor Name : ARCOFEMI HEALTHCARE LIMITED

DEPARTMENT OF IMMUNOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324



Dr Nidhi Sachdev M.B.B.S,MD(Pathology) Consultant Pathologist

SIN No:SPL24145219



Page 11 of 13





Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747 Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 02:17PM Received : 29/Oct/2024 02:32PM

Reported : 29/Oct/2024 04:41PM

: Final Report : ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Status

Test Name	Result	Unit	Bio. Ref. Interval	Method
COMPLETE URINE EXAMINATION (C	CUE) , URINE	ı		
PHYSICAL EXAMINATION				
COLOUR	PALE YELLOW		PALE YELLOW	Visual
TRANSPARENCY	CLEAR		CLEAR	Physical Measuremen
pH	6.0		5-7.5	Double Indicator
SP. GRAVITY	1.015		1.002-1.030	Bromothymol Blue
BIOCHEMICAL EXAMINATION				
URINE PROTEIN	NEGATIVE		NEGATIVE	Protein Error Of Indicator
GLUCOSE	NEGATIVE		NEGATIVE	Glucose Oxidase
URINE BILIRUBIN	NEGATIVE		NEGATIVE	Azo Coupling Reaction
URINE KETONES (RANDOM)	NEGATIVE		NEGATIVE	Sodium Nitro Prusside
UROBILINOGEN	NEGATIVE		NORMAL	Modifed Ehrlich Reaction
NITRITE	NEGATIVE		NEGATIVE	Diazotization
LEUCOCYTE ESTERASE	NEGATIVE		NEGATIVE	Leucocyte Esterase
CENTRIFUGED SEDIMENT WET M	OUNT AND MICROSCOPY	/ //		
PUS CELLS	1-2	/hpf	0-5	Microscopy
EPITHELIAL CELLS	2-3	/hpf	<10	Microscopy
RBC	ABSENT	/hpf	0-2	Microscopy
CASTS	NIL		0-2 Hyaline Cast	Microscopy
CRYSTALS	ABSENT		ABSENT	Microscopy

Comment:

All urine samples are checked for adequacy and suitability before examination. All abnormal chemical examination are rechecked and verified by manual methods. Microscopy findings are reported as an average of 10 high power fields.

Page 12 of 13



Dr.Kritika Jain M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:UR2418278





Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747 Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF

Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 02:17PM

Received : 29/Oct/2024 02:32PM Reported : 29/Oct/2024 04:41PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

DEPARTMENT OF CLINICAL PATHOLOGY

ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324

Test Name	Result	Unit	Bio. Ref. Interval	Method
URINE GLUCOSE(FASTING)	NEGATIVE		NEGATIVE	GOD-POD

*** End Of Report ***



Page 13 of 13



Dr.Kritika Jain M.B.B.S,M.D(Pathology) Consultant Pathologist

SIN No:UF012147





Age/Gender : 35 Y 6 M 26 D/M UHID/MR No : RIND.0000017747 Visit ID : RINDOPV19175

Ref Doctor : Dr.SELF Emp/Auth/TPA ID : 22E37239 Collected : 29/Oct/2024 02:17PM

Received : 29/Oct/2024 02:32PM Reported : 29/Oct/2024 04:41PM

Status : Final Report

: ARCOFEMI HEALTHCARE LIMITED Sponsor Name

TERMS AND CONDITIONS GOVERNING THIS REPORT

- 1. Reported results are for information and interpretation of the referring doctor or such other medical professionals, who understandreporting units, reference ranges and limitation of technologies. Laboratories not be responsible for any interpretation whatsoever.
- 2. It is presumed that the tests performed are, on the specimen / sample being to the patient named or identified and the verifications of parrticulars have been confirmed by the patient or his / her representative at the point of generation of said specimen.
- 3. The reported results are restricted to the given specimen only. Results may vary from lab to lab and from time to time for the same parameter for the same patient (within subject biological variation).
- 4. The patient details along with their results in certain cases like notifiable diseases and as per local regulatory requirements will be communicated to the assigned regulatory bodies.
- 5. The patient samples can be used as part of internal quality control, test verification, data analysis purposes within the testing scope of
- 6. This report is not valid for medico legal purposes. It is performed to facilitate medical diagnosis only.

Dr.Kritika Jain M.B.B.S,M.D(Pathology) Consultant Pathologist





FO Cradle

From:

noreply@apolloclinics.info

Sent: To: 28 October 2024 16:43

shivanshusharma004@gmail.com

Cc: Subject: fo.indira@apollocradle.com Your appointment is confirmed



Dear MR. SHARMA SHIVANSHU,

Greetings from Apollo Clinics,

Your corporate health check appointment is confirmed at Apollo Cradle & Children's Hospital Indirapuram clinic on 2024-10-29 at 08:00-08:30.

Payment Mode	
Corporate Name	ARCOFEMI HEALTHCARE LIMITED
Agreement Name	[ARCOFEMI MEDIWHEEL MALE AHC CREDIT PAN INDIA OP AGREEMENT]
Package Name	[ARCOFEMI - MEDIWHEEL - FULL BODY ANNUAL PLUS MALE - 2D ECHO - PAN INDIA - FY2324]

"Kindly carry with you relevant documents such as HR issued authorization letter and or appointment confirmation mail and or valid government ID proof and or company ID card and or voucher as per our agreement with your company or sponsor."

Note: Video recording or taking photos inside the clinic premises or during camps is not allowed and would attract legal consequences.

Note: Also once appointment is booked, based on availability of doctors at clinics tests will happen, any pending test will happen based on doctor availability and clinics will be updating the same to customers.

Instructions to be followed for a health check:



This is to certify that I have conducted the clinical examination

OF SHIVANSHU SHARMA On 30/10/24

After reviewing the medical history and on clinical examination it has been found that he/she is

		T				
•	Medically Fit	ı				
•	Fit with restrictions/recommendations					
	Though following restrictions have been revealed, in my opinion, these are not impediments to the job.					
	1					
	2					
	3					
	However the employee should follow the advice/medication that has been communicated to him/her.					
	Review after					
•	Currently Unfit.	T				
	Review afterrecommended					
•	Unfit Unsupplied Property Commended					
	Unfit Trend No Difference of the plant of t					
	Shaziabadi Dr.	-				
	Medical Officer	7				

This certificate is not meant for medico-legal purposes

Address: NH-1, Shakti Khand 2, Indirapuram, Ghaziabad, Utlar Pradesh – 201014, Ph No: +91 88106 85179, 1860 500 4424

Apollo Specialty Hospitals Private Limited

(Formerly known as Nova Specialty Hospitals Private Limited) CIN - U85100TG2009PTC099414

Date

: 29-10-2024

: 35 Y / Male

MR NO

: RIND.0000017747

Department

: GENERAL

Doctor

Apollo

Name

Age/ Gender

: Mr. SHIVANSHU SHARMA

Registration No.

Qualification

Cradle &Children's Hospital


Consultation Timing: 09:22


Height:	177 cm	Weight 86 Kg	BMI:	Waist Circum :
Temp:	98.2.E	Pulse 80	Resp : 18	B.P: 32 95

General Examination/Allergies History Cinical Diagnosis & Management Plan

Follow up date

Doctor Signature









Apollo Cradle

CONSENT FORM

Patient Name:	Shivanghy	Dame	Age: 34	
UHID Number:		Comp	pany Name: Bank]	Roscocia
I Mr/Mrs/Ms	Shiranshu	Slamp Emplo	a control self Charles and Control	
	int to inform you that I ich is a part of my routi		DENTA OF	THAT CHOCOLDI
And I claim the	above statement in m	y full consciousness.		
	die			
	11101		201-1-04	

Patient Signature:

KINDLY NOTE: GLUCOSE, POST	PRANDIAL (PP), URINE GLU	UCOSE(POST PRANDIAL), D	ENTAL , OPTHAL TEST DE	NIED BY PATIENT

Patient Name : Mr. SHIVANSHU SHARMA Age : 35 Y/M

UHID : RIND.0000017747 OP Visit No : RINDOPV19175 Conducted By: : Dr. SANJIV KUMAR GUPTA Conducted Date : 30-10-2024 10:58

Referred By : SELF

2D-ECHO WITH COLOUR DOPPLER

Dimensions:

Ao (ed) 3.04 CM LA (es) 3.17 CM LVID (ed) 4.31 CM LVID (es) 2.72 CM IVS (Ed) 1.31 CM 1.31 CM LVPW (Ed) EF 68.00% %FD 34.00%

MITRAL VALVE: NORMAL

AML NORMAL NORMAL NORMAL

AORTIC VALVE NORMAL

TRICUSPID VALVE NORMAL

RIGHT VENTRICLE NORMAL

INTER ATRIAL SEPTUM NORMAL

INTER VENTRICULAR SEPTUM INTACT

AORTA NORMAL

RIGHT ATRIUM NORMAL

LEFT ATRIUM NORMAL

Pulmonary Valve NORMAL

PERICARDIUM NORMAL

Patient Name : Mr. SHIVANSHU SHARMA Age : 35 Y/M

UHID : RIND.0000017747 OP Visit No : RINDOPV19175 Conducted By: : Dr. SANJIV KUMAR GUPTA Conducted Date : 30-10-2024 10:58

Referred By : SELF

NO REGIONAL WALL MOTION ABNORMALITY

NORMAL LEFT VENTRICULAR SYSTOLIC FUNCTION

COLOUR AND DOPPLER STUDIES NORMAL

PWD: A>E AT MITRAL INFLOW NORMAL

VELOCITY ACROSS THE AV NORMAL

IMPRESSION:

GOOD LV/RV FUNCTION

NO MR/NO AR /NO TR/NOPAH.NO CLOT

NO PERICARDIAL EFFUSION.



Patient Name : Mr. SHIVANSHU SHARMA Age : 35 Y/M

UHID : RIND.0000017747 OP Visit No : RINDOPV19175 Conducted By: : Dr. SANJIV KUMAR GUPTA Conducted Date : 30-10-2024 10:58

Referred By : SELF

GUPTA



Patient Name : Mr. SHIVANSHU SHARMA Age/Gender : 35 Y/M

 UHID/MR No.
 : RIND.0000017747
 OP Visit No
 : RINDOPV19175

 Sample Collected on
 : 29-10-2024 16:52

Ref Doctor : SELF **Emp/Auth/TPA ID** : 22E37239

DEPARTMENT OF RADIOLOGY

ULTRASOUND - WHOLE ABDOMEN

LIVER: Liver is enlarged in size (19.9cm) and the parenchymal echotexture shows grade-2 diffuse fatty infiltration. Intra-hepatic biliary radicals are not dilated. Portal vein is normal in course and calibre.

GALL BLADDER: Gall bladder appears echo free with normal wall thickness. No pericholecystic fluid noted. Common duct is not dilated.

PANCREAS: Pancreas is normal in size and echopattern.

SPLEEN: Spleen is normal in size, shape and echopattern. No focal lesion seen. Hilum is normal.

KIDNEYS: Both the kidneys are normal in position, shape, size, outline and echotexture. Cortico-medullary differentiation of both kidneys is maintained. Central sinus echoes are compact.

Visualized parts of the retroperitoneum do not reveal any lymphadenopathy.

URINARY BLADDER: Urinary bladder is normal in wall thickness with clear contents. No obvious mass lesion seen.

PROSTATE: Prostate is normal in size and echo-pattern. Capsule is intact.

No free fluid is seen in the peritoneal cavity.

IMPRESSION: Hepatomegaly with grade 2 Fatty infiltration of the liver.

SUGGEST CLINICAL CORRELATION

(The sonography findings should always be considered in correlation with the clinical and other investigation finding where applicable.) It is only a professional opinion, Not valid for medico legal purpose.



Patient Name : Mr. SHIVANSHU SHARMA Age/Gender : 35 Y/M

 $\begin{array}{c} \textbf{Dr. SANGEETA AGGARWAL} \\ \underline{\frac{MBBS, MD}{Radiology}} \end{array}$



Patient Name : Mr. SHIVANSHU SHARMA Age/Gender : 35 Y/M

 UHID/MR No.
 : RIND.0000017747
 OP Visit No
 : RINDOPV19175

 Sample Collected on
 : 29-10-2024 14:20

Ref Doctor : SELF **Emp/Auth/TPA ID** : 22E37239

DEPARTMENT OF RADIOLOGY

X-RAY CHEST PA

Both the lung fields and hilar shadows appears normal.

There is no obvious active pleuro-parenchymal lesion seen.

Both the costophrenic and cardiophrenic angles are clear.

Cardiac size appears within normal limits.

Both dome of hemidiaphragms are normal in position and contour.

Thoracic wall and soft tissues under view appear normal.

CONCLUSION:

No obvious abnormality seen

Dr. SANGEETA AGGARWAL MBBS, MD

Radiology